The large increase in OPN expression in tumors compared with normal tissue and its association with survival suggest a role for OPN in lung tumorigenesis.

Osteopontin overexpression is common in primary non-small cell lung cancer (NSCLC) and may be important in the cancer development and progression and osteopontin plasma levels may serve as a biomarker for diagnosing or monitoring patients with NSCLC.

Results support the hypothesis of an association between high osteopontin expression and poor survival of patients with stage I non-small cell lung cancer, suggesting that osteopontin could be a candidate target for cancer therapy.

High osteopontin expression is associated with non-small cell lung cancers

OPN plays a crucial role for tumor growth and angiogenesis of human lung cancer cells in vivo by interacting with alphavbeta3 integrin.

Frequent osteopontin expression is typical of, but not specific for malignant pleural mesothelioma, whereas it appears to select pulmonary adenocarcinoma cases with p65 and MMP-9 expression, suggesting a link with EGFR signalling pathways.

Osteopontin over-expression is considerably correlated with lymph node metastasis in non-small cell lung cancers.

OPN contributs to the migration of lung cancer cells

Correlation of OPN protein expression and bone metastasis in non-small-cell lung cancer needs further investigation.

osteopontin nd beta-catenin are useful in differentiating small cell lung carcinomas and non-small cell lung carcinomas

High serum levels and high mRNA expression of Gal-3 and OPN in non-small cell lung cancer are closely related to the occurrence and metastasis of NSCLC.

elevated plasma osteopontin levels are associated with resection of non-small-cell lung cancer.

OPNa expression was increased in non-small cell lung cancer.

High Osteopontin is associated with lung cancer.

In this study we demonstrated that AhR positively regulates OPN expression in lung cancer.

Overexpression of osteopontin, alphavbeta3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer.

The preoperative serum osteopontin level was a useful predictor of an unfavorable prognosis, and it was an independent prognostic determinant of outcome in patients who underwent surgery for non-small-cell lung cancer

osteopontin, LAMB3 and ITGB1 played important roles in the occurrence and metastasis of lung cancer, thus provided important clues to understanding the molecular mechanism of metastasis.

OSTEOPONTIN -443C/T polymorphism is a potential predictive marker of survival in lung cancer patients, it is correlated with bone metastasis significantly.

The level of OPN expression in lung adenocarcinoma was associated with decreased apoptotic activity of tumor cells, and correlated with alphav integrin expression, particularly in low stage tumors.

Osteopontin is a prognostic biomarker in non-small cell lung cancer.

secreted phosphoprotein-1 in pleural effusion can be used for the auxiliary diagnosis of MPE and used to determine the prognosis of patients with non-small cell lung cancer

Data indicate that the osteopontin (OPN) expression rate in non-small cell lung carcinoma (NSCLC) tissue was higher than normal tissue.

OPN is commonly expressed in non-small cell lung cancer(NSCLC) and may guide the evaluation of prognosis with NSCLC, especially for early-stage patients.

The present meta-analysis is consistent with the hypothesis that increased expression of OPN protein may be significantly associated with poor prognosis in patients with on-small-cell lung cancer.

Inhibition of p90 ribosomal S6 kinase attenuates cell migration and proliferation of the human lung adenocarcinoma through phospho-GSK-3beta and osteopontin.

Results show that the presence of OPN and TSP-1 in the serum of patients with non-small cell lung cancer may reflect the aggressiveness of the tumor.

ITGbeta3 and CD44 expression levels determine whether OPN-a inhibits or enhances growth in lung cancer cells.

OPN-a may represent a bone metastatic factor in human lung cancer, as well as a potential therapy target

Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma.

High SPP1 expression is associated with Small Cell lung cancer.

Our results suggest that SPP1 enhanced the second-generation EGFR TKI resistance in lung cancer, and inhibiting SPP1 might be a therapeutic target to overcome afatinib resistance.

These findings indicated that ADH1C and SPP1 might be novel promising biomarkers for predicting lung adenocarcinoma prognosis.

12 studies with osteopontin (OPN) levels were included in META-ANALYSIS. Significant differences in blood OPN levels were seen between patients with benign lung disease and healthy participants compared with patients with malignant pleural mesothelioma (MPM), but not when comparing participants with cancer with MPM participants. There were not enough studies reporting OPN levels in pleural fluid to complete meta-analysis.

Reduced levels of FSTL1 were detected in various tumors and were associated with poor clinical outcome in patients with non-small cell lung cancer. FSTL1 expression negatively correlated with the metastatic potential of lung cancer cells. FSTL1 directly bound to the proform of SPP1/osteopontin, restraining proteolytic activation of SPP1, which led to inactivation of integrin/CD44-associated signaling.

OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase.

SPP1 is over-expressed in diverse cancers including breast, bladder, colorectal, head, neck, liver, lung, and esophageal cancers.

Prognostic value of OCT4A and SPP1C transcript variant co-expression in early-stage lung adenocarcinoma.

Understanding the molecular association between hyperkalemia and lung squamous cell carcinomas.

OPN is positively involved in the formation of MPE of lung cancer presumably by promoting VEGF secretion from vascular endothelial cells or mesothelial cells.

Results show that aerosol delivery of osteopontin triple mutant successfully suppresses lung cancer development in the K-ras (LA1) mouse model.